Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Provided By GlobeNewswire
Last update: Jan 21, 2025
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS").
Read more at globenewswire.com21.62
-0.43 (-1.95%)
Find more stocks in the Stock Screener
CPRX Latest News and Analysis
10 days ago - ChartmillWhy NASDAQ:CPRX qualifies as a high growth stock.A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.
11 days ago - ChartmillInvestors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued.
12 days ago - ChartmillUnlocking the Growth Potential of NASDAQ:CPRX.A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
13 days ago - ChartmillExploring NASDAQ:CPRX's high growth characteristics.CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX).
16 days ago - ChartmillWhy NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.
18 days ago - ChartmillNASDAQ:CPRX: good value for what you're paying.Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.
